IBRXearnings
- Next report
- No date yet
- none in the next 8 weeks
- Last result
- −$0.09Missed
- vs −$0.08 expected on Nov 9
- Stock move on it
- −15.17%
- one session
- Price
- $6.03
- −9.52% today · $8.68B cap
Past and upcoming reports
1
| Nov 9, 2026 | Sep 30, 2026 | Time not given | −$0.08 | Missed−$0.09 | −15.17% |
After the report
Nov 9, 2026 report
IBRX missed EPS estimates as ANKTIVA growth remained offset by profitability and financing risks
ImmunityBio reported September-quarter EPS of -$0.09 versus -$0.05 estimated, an 84.8% miss. Guidance was not provided in the payload. the stock closed at $6.665, down 1.19% on November 11, while the next ANKTIVA sales update remained the key forward catalyst.
Reported against expected
MissedReported EPS was -$0.09 versus -$0.05 estimated, a $0.04 shortfall and 84.8% miss, for the quarter ended September 30, 2026.
Guidance
No formal forward guidance or quantitative outlook was provided in the payload.
How the stock reacted
IBRX closed at $6.665 on November 11, down $0.08 or 1.19%. event-day and subsequent reaction-window returns were unavailable.
What changed
EPS was -$0.09 versus -$0.05 expected, while reported revenue growth remained +192.9% TTM.
What the price now assumes
The $6.665 close below the 20-day SMA of $8.31 reflects skepticism despite price remaining above the 200-day SMA of $6.33.
What it means for the business
Maintain a cautious growth bias. upgrade only if the next ANKTIVA sales update reduces financing risk without worsening the -151.9% operating margin.
The next one to three months, as we saw it then
Better case33%
ANKTIVA sales momentum could support re-rating if the next sales update confirms continued commercial traction and financing pressure eases.
Base case33%
Growth remains credible, but the EPS miss, -151.9% operating margin, and unresolved financing risk keep the stock range-bound.
Worse case33%
A revenue shortfall could force capital raising on unfavorable terms, compounding the EPS miss and weak operating economics.
If you hold it
Hold unless next-quarter revenue misses guidance materially or customer concentration risk worsens.
If you are watching
Add only if next-quarter guidance is reiterated or raised. avoid if guidance is cut or geopolitical risk escalates.
Scenario odds are a judgement, not measured.